Semiglazov Vf

33.9k total citations · 9 hit papers
239 papers, 11.9k citations indexed

About

Semiglazov Vf is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Semiglazov Vf has authored 239 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 173 papers in Oncology, 100 papers in Cancer Research and 69 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Semiglazov Vf's work include Breast Cancer Treatment Studies (88 papers), Cancer Treatment and Pharmacology (72 papers) and HER2/EGFR in Cancer Research (71 papers). Semiglazov Vf is often cited by papers focused on Breast Cancer Treatment Studies (88 papers), Cancer Treatment and Pharmacology (72 papers) and HER2/EGFR in Cancer Research (71 papers). Semiglazov Vf collaborates with scholars based in Russia, Spain and United States. Semiglazov Vf's co-authors include Pinuccia Valagussa, Luca Gianni, W. Eiermann, Aňa Lluch, Tadeusz Pieńkowski, Graham Ross, José Baselga, Giulia Bianchi, Eva Ciruelos and А. А. Божок and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Semiglazov Vf

214 papers receiving 11.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

2011 1.5k citations Luca Gianni, Semiglazov Vf et al. profile →
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2010 891 citations Luca Gianni, Semiglazov Vf et al. profile →
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

2013 700 citations Semiglazov Vf, Eva Ciruelos et al. profile →
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

2016 555 citations Luca Gianni, Semiglazov Vf et al. profile →
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

2006 548 citations Pinuccia Valagussa, Semiglazov Vf et al. profile →
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 530 citations Semiglazov Vf et al. Annals of Oncology profile →
Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

2005 505 citations Semiglazov Vf et al. profile →
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

2009 504 citations Semiglazov Vf, Richard Greil et al. profile →
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

2022 204 citations Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Semiglazov Vf

Since Specialization

Citations

This map shows the geographic impact of Semiglazov Vf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Semiglazov Vf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Semiglazov Vf more than expected).

Fields of papers citing papers by Semiglazov Vf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Semiglazov Vf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Semiglazov Vf. The network helps show where Semiglazov Vf may publish in the future.

Co-authorship network of co-authors of Semiglazov Vf

This figure shows the co-authorship network connecting the top 25 collaborators of Semiglazov Vf. A scholar is included among the top collaborators of Semiglazov Vf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Semiglazov Vf. Semiglazov Vf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Late Complications of Breast Cancer Treatment: Osteoporosis, Cardiotoxicity, Fertility Disorders (Part 2) 2025 ·Voprosy Onkologii ·Т. Yu. Semiglazova, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Elena Tkachenko, (unknown), (unknown), (unknown), (unknown), Е. A. Ulrikh, В. В. Семиглазов, (unknown), Petr Krivorotko, Semiglazov Vf	0
2	Breast cancer during pregnancy: an oncologist’s viewpoint 2025 ·Tumors of female reproductive system ·(unknown), Petr Krivorotko, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Т. Yu. Semiglazova, Е. A. Ulrikh, Semiglazov Vf	0
3	Age-Related Features of the Prevalence, Early Diagnosis and Survival of Breast Cancer Patients (Clinical and Population-Based Study) 2024 ·Voprosy Onkologii ·Merabishvili Vm, Semiglazov Vf, (unknown)	1
4	Reconstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reconstruction failure 2024 ·P A Herzen Journal of Oncology ·(unknown), Petr Krivorotko, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. М. Belyaev, Semiglazov Vf	4
5	Late Complications of Chemotherapy and Hormone Therapy in the Cancer: General Weakness, Cognitive Impairment, Peripheral Neuropathy, Treatment-Induced Myeloproliferative Diseases (Part 1) 2024 ·Voprosy Onkologii ·Т. Yu. Semiglazova, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Elena Tkachenko, (unknown), В. В. Семиглазов, (unknown), Petr Krivorotko, Semiglazov Vf	0
6	Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer 2024 ·Russian Journal of Archive of Pathology ·(unknown), Т. Yu. Semiglazova, (unknown), (unknown), (unknown), (unknown), В. В. Семиглазов, Petr Krivorotko, Semiglazov Vf	2
7	LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study 2023 ·Annals of Oncology ·Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, A. Antón Torres, Giampaolo Bianchini, (unknown), Stefania Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, (unknown), Hoda Ali, Giuseppe Viale	10
8	Prognostic and predictive value of a novel 100-point scale in patients with T1–2N0M0 breast cancer 2023 ·SHILAP Revista de lepidopterología ·Р. М. Палтуев, (unknown), Semiglazov Vf, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
9	Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study breakdown → 2022 ·Annals of Oncology ·Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Marc Thill, A. Antón, Stefania Zambelli, Giampaolo Bianchini, Salvatore Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, (unknown), Pinuccia Valagussa, Giuseppe Viale	204
10	Utility of dual-energy contrast-enhanced spectral mammography for the diagnosis of multicentric breast cancer 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Petr Krivorotko, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Semiglazov Vf	1
11	The role of digital mammography, scintimammography with <sup>99m </sup>Tc-methoxyisobutylisonitrile (MIBI) and ultrasound in the diagnosis of multicentric breast cancer 2019 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Petr Krivorotko, (unknown), (unknown), (unknown), Semiglazov Vf, (unknown), (unknown)	3
12	[Breast cancer: clinical and experimental research]. 2018 ·PubMed ·Semiglazov Vf	0
13	NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER 2018 ·Siberian Journal of Oncology ·Semiglazov Vf, В. В. Семиглазов, G. A. Dashyan, Petr Krivorotko, В Г Иванов, (unknown), Р. М. Палтуев, (unknown), Т. Yu. Semiglazova, (unknown), (unknown), (unknown), (unknown), (unknown)	2
14	CLINICAL AND BIOLOGICAL MODEL FOR EVALUATION OF THE EFFECTIVENESS OF SYSTEMIC THERAPY FOR BREAST CANCER 2018 ·Voprosy Onkologii ·Semiglazov Vf, (unknown), (unknown), А. М. Belyaev, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), В. В. Семиглазов, (unknown), (unknown), Т. Yu. Semiglazova, G. A. Dashyan, Petr Krivorotko, (unknown)	1
15	Regeneration and Cicatrization. 2016 ·PubMed ·(unknown), (unknown), (unknown), (unknown), Semiglazov Vf	2
16	Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer 2014 ·SHILAP Revista de lepidopterología ·Т. Yu. Semiglazova, В. В. Семиглазов, (unknown), Petr Krivorotko, (unknown), Semiglazov Vf	1
17	[Adjuvant chemotherapy for breast cancer: search for new ways of planning]. 2014 ·PubMed ·Semiglazov Vf, В. В. Семиглазов, Р. М. Палтуев, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Т. Yu. Semiglazova	1
18	[Strategic and practical approaches to solving the problem of breast cancer]. 2012 ·PubMed ·Semiglazov Vf	1
19	[Comprehensive radiographic diagnosis of breast cancer]. 1996 ·PubMed ·(unknown), (unknown), Semiglazov Vf, (unknown), (unknown), (unknown)	1
20	[Excretion of cyclic adenosine monophosphate in breast and lung cancer]. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·(unknown), Semiglazov Vf, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact